Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ALVAL.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
N/A
-0.41
vs -0.66
Q4.20
N/A
-0.12
vs -0.51
Q2.21
N/A
-0.40
vs -0.41
Q4.21
N/A
-0.54
vs -0.12
Q2.22
N/A
-0.52
vs -0.40
Q4.22
N/A
-0.69
vs -0.54
Q2.23
N/A
-0.16
vs -0.52
Q4.23
N/A
-0.44
vs -0.69
Q2.24
N/A
-0.28
vs -0.16
Q4.24
N/A
-0.41
vs -0.44
Sales Growth
YoY
Current
Estimates
Q2.20
+163%
121K vs 46K
Q4.20
+6502%
3M vs 45K
Q2.21
+22%
148K vs 121K
Q4.21
-95%
150K vs 3M
Q2.22
+329%
635K vs 148K
Q4.22
NA
150K vs 150K
Q2.23
+568%
4.2M vs 635K
Q4.23
+227%
490K vs 150K
Q2.24
-99%
35K vs 4.2M
Q4.24
-71%
140K vs 490K
Return on Equity
QoQ
Q2.21
-19%
-0.19
vs -0.13
Q4.21
-37%
-0.37
vs -0.19
Q2.22
-52%
-0.52
vs -0.37
Q4.22
-54%
-0.54
vs -0.52
Q2.23
-17%
-0.17
vs -0.54
Q4.23
-28%
-0.28
vs -0.17
Q2.24
-21%
-0.21
vs -0.28
Q4.24
-63%
-0.63
vs -0.21
Institutionnal Ownership
Quote Panel
Key Metrics
Relative Strength
ALVAL.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
PAR
Unprofitable
Unprofitable
-0.00 ( -0.48%)
Relative Strenght
Volume Buzz
-9%
Earning Acce
No
Dist 52w H.
56%Forecast
1162%2025-Revenue
-21%2025-EPS
73%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ALVAL.PA compares to sector?